Implant Sciences
This article was originally published in The Gray Sheet
Executive Summary
Brachytherapy firm hopes to receive 510(k) clearance by year-end for its ytterbium-169 breast cancer treatment. The company expects to receive a NIH grant within weeks to "fabricate a prototype treatment for performing this procedure and to measure the radiation dose pattern," according to a release. Ytterbium-169 could potentially replace post-lumpectomy breast cancer treatment involving external beam therapy or brachytherapy with higher-energy iridium-192...